FDA-cleared profile

Diagnocat

DGNCT, LLC · CBCT · FDA-cleared (510(k))

Authorized purpose: Diagnocat is an automated concurrent-read aid for detecting periapical radiolucency on permanent teeth in previously acquired, clinically justified maxillofacial CBCT; it is a second-read aid and does not replace complete dental-professional review or judgment.

Clinical role
Automated concurrent second-read support for periapical-radiolucency detection on permanent teeth.
Images and patients
CBCT · Maxillofacial region; permanent teeth; periapical radiolucency
Key limitation
Keep in mind: Diagnocat is a second-read aid and does not replace complete dental review or clinical judgment. The cleared population, permanent dentition, maxillofacial CBCT, clinically justified acquisition, and trained-user limits apply.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Diagnocat is an automated concurrent-read aid for detecting periapical radiolucency on permanent teeth in previously acquired, clinically justified maxillofacial CBCT; it is a second-read aid and does not replace complete dental-professional review or judgment.
  • Which images or clinical context are in scope?Modality: CBCT Anatomy or clinical context: Maxillofacial region; permanent teeth; periapical radiolucency Input: Previously acquired, clinically justified maxillofacial CBCT studies of patients with permanent teeth.
  • Who uses it?Intended users: Professionally trained and licensed dental professionals with at least two years of CBCT reading experience.
  • What does the software produce?Output: Tooth detection, localization or segmentation, and candidate periapical-radiolucency findings in a web or desktop review application.
  • What is its most important limitation?Key limitation: Diagnocat is a second-read aid and does not replace complete dental review or clinical judgment. The cleared population, permanent dentition, maxillofacial CBCT, clinically justified acquisition, and trained-user limits apply.

Clinical takeaway. Clinical role: Diagnocat is an automated concurrent-read aid for detecting periapical radiolucency on permanent teeth in previously acquired, clinically justified maxillofacial CBCT; it is a second-read aid and does not replace complete dental-professional review or judgment.

Evidence takeaway. Evidence from the reviewed source record: The FDA package documents automated tooth and periapical-radiolucency analysis verification for the cleared concurrent-read workflow; no exact-version independent outcome claim was promoted.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Diagnocat is an automated concurrent-read aid for detecting periapical radiolucency on permanent teeth in previously acquired, clinically justified maxillofacial CBCT; it is a second-read aid and does not replace complete dental-professional review or judgment.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Automated concurrent second-read support for periapical-radiolucency detection on permanent teeth.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Previously acquired, clinically justified maxillofacial CBCT studies of patients with permanent teeth.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Tooth detection, localization or segmentation, and candidate periapical-radiolucency findings in a web or desktop review application.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Dental and maxillofacial imaging workflows using clinically justified CBCT examinations.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Professionally trained and licensed dental professionals with at least two years of CBCT reading experience.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Diagnocat is a second-read aid and does not replace complete dental review or clinical judgment. The cleared population, permanent dentition, maxillofacial CBCT, clinically justified acquisition, and trained-user limits apply.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The FDA package documents automated tooth and periapical-radiolucency analysis verification for the cleared concurrent-read workflow; no exact-version independent outcome claim was promoted.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA package documents automated tooth and periapical-radiolucency analysis verification for the cleared concurrent-read workflow; no exact-version independent outcome claim was promoted.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
85.4%
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
99.1%
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252934 FDA evidence package for Diagnocat

  • DesignFDA 510(k) verification and validation evidence described in the exact submission
  • PopulationMaxillofacial region; permanent teeth; periapical radiolucency
  • Scopeexact submission
  • Tested versionDiagnocat
  • IndependenceSponsor or vendor study

K252934

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no candidate record for K252934; no exact native submission identifier match was found.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Previously acquired, clinically justified maxillofacial CBCT studies of patients with permanent teeth.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K252934: Diagnocat

  2. Routing

    Source context, not route validation: The FDA package describes DICOM CBCT input and web or desktop outputs; exact local routing, viewer, archive, and reporting interfaces require testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K252934: Diagnocat

  3. AI processing

    Source context, not route validation: The FDA package describes web and desktop application forms; current hosting, network, security, and local operational configuration remain unverified.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K252934: Diagnocat

  4. Returned objects

    Source context, not route validation: Tooth detection, localization or segmentation, and candidate periapical-radiolucency findings in a web or desktop review application.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K252934: Diagnocat

  5. Viewer/worklist/report

    Unresolved route: Tooth detection, localization or segmentation, and candidate periapical-radiolucency findings in a web or desktop review application.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K252934: Diagnocat

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes web and desktop application forms; current hosting, network, security, and local operational configuration remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
The FDA package describes DICOM CBCT input and web or desktop outputs; exact local routing, viewer, archive, and reporting interfaces require testing.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Only professionally trained and licensed dental professionals with at least two years of cbct reading experience. should operate or interpret this product. Local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K252934 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Diagnocat is a second-read aid and does not replace complete dental review or clinical judgment. The cleared population, permanent dentition, maxillofacial CBCT, clinically justified acquisition, and trained-user limits apply.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map the installed product, build, options, population, anatomy, inputs, outputs, and enabled functions to K252934 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The FDA package describes web and desktop application forms; current hosting, network, security, and local operational configuration remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment details do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes DICOM CBCT input and web or desktop outputs; exact local routing, viewer, archive, and reporting interfaces require testing.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Diagnocat is a second-read aid and does not replace complete dental review or clinical judgment. The cleared population, permanent dentition, maxillofacial CBCT, clinically justified acquisition, and trained-user limits apply.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price or product-specific reimbursement was established in the reviewed public material.

Lifecycle monitoring

Monitor K252934 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Diagnocat is a second-read aid and does not replace complete dental review or clinical judgment. The cleared population, permanent dentition, maxillofacial CBCT, clinically justified acquisition, and trained-user limits apply.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252934
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CBCT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Maxillofacial region; permanent teeth; periapical radiolucency
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-01-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-04Last searched
25Fields reviewed
10Source classes checked
20Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

Screened 20 PubMed titles and one trial record. Some concern dental AI, CBCT, or periapical radiolucency, but none identifies Diagnocat, K252934, and the tested release; all 21 are quarantined. The current discovery snapshot contains 20 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared product version was established. Obtain a written quote separating license, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The FDA decision material does not establish the complete security posture for the exact product and deployment. Obtain architecture, identity, audit, encryption, retention, support-access, vulnerability-management, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K252934: Diagnocat

    U.S. Food and Drug Administration - Published 2026-01-15 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Diagnocat model card (K252934)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K252934 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253009

DS Core Detect

Dentsply Sirona, Inc.

Authorized purpose: Concurrent-read incidental detection of permanent teeth that may be associated with periapical radiolucencies in CBCT data acquired for other reasons.

Modality
CBCT
Anatomy
Permanent teeth and periapical dental structures
Decision
2026-01-07
FDA-cleared K260785

DS Core CBCT Anatomy

Dentsply Sirona

Authorized purpose: DS Core CBCT Anatomy uses CBCT and digital-impression data to provide tooth and jaw segmentation, inferior-alveolar-nerve-canal segmentation, panoramic-curve support, and registration for dental professionals.

Modality
CBCT
Anatomy
Teeth; jaws; and the inferior alveolar nerve canal
Decision
2026-04-23
FDA-cleared K252538

CEPHX3D

Orca Dental AI, Ltd.

Authorized purpose: CEPHX3D processes dental and craniomaxillofacial images to support diagnosis and treatment planning, including three-dimensional models, viewing, segmentation, measurements, and dental-solution design input for patients age 12 and older.

Modality
CBCT
Anatomy
Dental and craniomaxillofacial anatomy
Decision
2026-03-05
FDA-cleared K251514

Overjet CBCT Assist

Overjet, Inc.

Authorized purpose: Dental and craniomaxillofacial CBCT segmentation, measurement and visualization support

Modality
CBCT
Anatomy
Dental/Maxillofacial
Decision
2025-12-05

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history